psychedelics
Inside the Dispute Over a High-Profile Psychedelic Study
A recent paper offered a theory on how psilocybin works to treat depression. Before long, there were memes and accusations of unprofessionalism.
Psychedelic Patents are Broken Because the Patent System Is Broken
Pharmaceutical patents are used to extend monopolies, leading to high drug prices, and reduced access. Will the psychedelic industry follow suit?
How One Man Tried to Build a DMT-Based Cult on Reddit and Lost Everything
In his mid-50s, a depressed, Yale-trained scientist took a potent psychedelic, saw God, and set out to spread the word. Within two years, he was dead.
Can the Clever Use of Old Legal Strategies Thwart Psychedelic Monopolies?
Corporations are going to use IP law to profit from psychedelics. But creative strategies from other industries could help people push back against exclusionary ownership and keep drugs accessible.
It’s Time to Start Studying the Downside of Psychedelics
Before psychedelic therapy and services becomes widely available, there needs to be a better understanding of all the ways these experiences can go wrong.
Love & Other Drugs: The Couples Using Psychedelics as a Way To Get Closer
“We’ve had some very bad fights in our relationship but facing these issues and talking about them after tripping together made us realise how grateful we are for each other.”
The Insights Psychedelics Give You Aren’t Always True
The study of false—sober—insights teaches us to be wary of accepting every realization from psychedelic trips without critical thinking.
The Future of Psychedelic Medicine Will Be Drugs You’ve Never Heard Of
Scientists are designing new psychedelic-inspired drugs that don’t yet exist, which might have effects no one can yet describe.
The Battle Over Psychedelic Therapy's Future
In a new documentary, VICE News explores what legal psychedelic therapy and access will be like in the US, and if it will be accessible.
Psychedelics Rejected for Therapeutic Use in Australia
The country’s medical regulator has rejected an application to have MDMA and psilocybin legalised for clinical use, citing a lack of evidence.
New Filing Challenges Compass Pathways’ Infamous Patent on Synthetic Psilocybin
The non-profit Freedom to Operate used research from chemists and crystallographers to argue in a legal filing that Compass’ form of synthetic psilocybin is not a new invention.